Nipro newsletter April 2026
tjoapck banner – feb 2026
Carterra 23/09/25
LB Bohle – 10.06.2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Merxin March 2026
Chemspec Feb 2026
the bridge – website ad 28/01/2026
Terumo 05/01
SAE Media – pre-filled syringes – East Coast 19/11/25
SAE Media – Pre-filled syringes West Coast 19/11/25
Nipro April 2026

CluePoints Receives €6 Million Growth Investment

Funding will grow both operations and business development in the U.S
Cambridge, MA – CluePoints, a leading software provider of risk-based monitoring (RBM) solutions for clinical trials, has today announced that it has secured a €6million investment to support its future growth, technology innovation and expansion. The new funding will allow CluePoints to grow both operations and business development in the U.S, and enable the company to continue expanding its portfolio of industry-leading monitoring solutions.
 
The funding has been secured from a combination of private and public investors including CluePoints founder Marc Buyse, former CEO of UCB, Roch Doliveux, and Belgium-based SRIW, Theodorus and Nivelinvest, and will allow CluePoints to further its leading position in the growing RBM market, and build its relationships with regulatory agencies.
 
CluePoints’ Central Statistical Monitoring (CSM) algorithms provide an agnostic approach to RBM that uses statistical methodology to identify unexpected or unusual patterns in clinical trial databases. Through its patented software engine, SMART™, CSM has the powerful ability to identify anomalous data and site errors, allowing improvement in data quality, optimization of on-site monitoring and a significant reduction in overall regulatory submission risk.
 
CluePoints’ CEO, Fran?ois Torche, comments: “CluePoints has been instrumental in driving a new way of thinking across the industry in terms of RBM techniques, with many of the top 10 pharmaceutical companies now utilizing CSM technology in their clinical trials. Our central monitoring platform’s specialized capability to process both clinical data and operational data to build the next generation of Key Risk Indicators (KRIs), is providing the most comprehensive solution in the field. As we continue to strengthen not only our software but also our consulting arm with industry-leading experts, this investment is a big step forward for us and will allow us to accelerate our plans and enhance our standing as the only provider of CSM technology in the industry.”
 
For further information on CluePoints’ solutions, please visit www.CluePoints.com
 

SMI London
Biopharma group march 2026
Interpack Staubli March 2026
Silgan March 2026
Scott Pharma – 25.03.2025
Bespak – 21.05.2025
Aptar – 08/01/2026
Stoelzle – 15th May 2025
L.B. Bohle – 08.04.2025